Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q2 FY26 Earnings Presentation
17 slides from Syngene International's earnings presentation, Nov 6, 2025
Slide 1: Syngene International Q2 FY26 Earnings Call
Syngene International Q2 FY26 Earnings Call 6 November 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: CEO Remarks
CEO Remarks Peter Bains Managing Director & CEO Syngene International Limited Putting Science to Work 3
Slide 4: Q2 FY26: Financial Performance
Q2 FY26: Financial Performance Revenue from Operations Sales Split (Q2 FY26) INR 911 Cr ( 2% Y-o-Y | 4% sequentially) Continued momentum in Research Services. Anticipated inventory correction in biologics manufacturing. 33% Operating EBITDA & Margin Research Operating EBITDA INR 200 Cr ( - 18 % Y-o-
Slide 5: Syngene maintains annual revenue guidance
Option 1 Syngene maintains annual revenue guidance The performance for the first half of FY26 aligns with our annual revenue guidance, and we expect a stronger second half. Putting Science to Work 5
Slide 6: Segment Highlights: Research Services
Segment Highlights: Research Services Awarded with a global Phase 3 clinical trial by a U.S. based biotech company. The trial will recruit patients across clinical sites in India and the U.S. and leverage advanced technology. Syngene also expanded its clinical trial footprint across Australia, New Z
Slide 7: Segment Highlights: CDMO Services
Segment Highlights: CDMO Services Building on existing capabilities and investing in new modalities including ADCs and Peptides. Expanding our biologics facility in Bengaluru with a GMP bioconjugation suite, accelerating ADC development timelines. Increase scale in peptides with clinical and commer
Slide 8: Broader Industry Dynamics
Broader Industry Dynamics 2025 Biotech funding shows signs of improvement 28 25 24 23 23 19 18 19 16 16 16 16 15 14 13 15 16 13 13 11 14 12 14 13 13 12 12 13 11 11 9 4Q22 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24
Slide 9: CEO's Concluding Remarks
CEO’s Concluding Remarks First half and second quarter performance aligned with expectations Underlying business remains strong Investment and progress in clinical trials and new modalities – ADCs and Peptides We are maintaining annual guidance Putting Science to Work 9
Slide 10: CFO Remarks
CFO Remarks Deepak Jain Chief Financial Officer Syngene International Limited Putting Science to Work 10
Slide 11: Q2 FY26: Performance in-line with expectations
Q2 FY26 : Performance in-line with expectations Q2 FY26 Revenue from Operations (INR Cr) 1000 Q2 FY26 growth +2% Y-o-Y ; 4% sequential growth (reported currency) 950 -3% Y-o-Y (constant currency) 911 • Continued Y-o-Y growth trajectory for Research services 900 891 led by volume improvement in disco
Slide 12: Costs and Profitability: Q2 FY26
Costs and Profitability : Q2 FY26 Reported PAT before exceptional items down 37% Y-o-Y % of Revenue from operations (INR Cr) Q2 FY25 Q2 FY26 Y-o-Y Change Operating EBITDA Margin 27% 22% -556 bps Raw material cost 27% 26% 1% 106 Staff cost 30% 34% 13% Q2 FY25 67 Q2 FY26 Other Direct cost 3% 3% 4% Oth
Slide 13: Capex Summary: USD 10 Mn Invested in Q2 FY26
Capex Summary: USD 10 Mn Invested in Q2 FY26 Capex Spend (%) 20% ~50% Q2 FY26 ~30% Research CDMO Others Putting Science to Work 13
Slide 14: H1 Performance: In-line with Guidance
H1 Performance: In-line with Guidance H1 FY26 Revenue from Operations (INR Cr) % of Revenue from operations H1 FY25 H1 FY26 Y-o-Y Reported PAT before exceptional 1,785 Change items down 4% y-o-y 1800 (INR Cr) Operating EBITDA 1750 25% 23% ~(200 bps) Margin 1700 1,681 161 Raw material cost 28% 26% -3
Slide 15: Guidance for Full Year FY26 Maintained
Guidance for Full Year FY26 Maintained Overall Syngene FY26 Guidance given Revenue from Ops Growth Mid Single digit Operating EBITDA Margin Mid 20s PAT growth before exceptions Negative Capex (USD Mn) 55 Putting Science to Work 15
Slide 16: Q&A
Q&A Putting Science to Work Putting Science to Work
Slide 17: Putting Science to Work
© 2025 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the trademark
Syngene International — Q2 FY26 Earnings Presentation on 6ix